<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18793">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862236</url>
  </required_header>
  <id_info>
    <org_study_id>10-2016</org_study_id>
    <nct_id>NCT02862236</nct_id>
  </id_info>
  <brief_title>The Relationship Between Common Psychiatric Drugs and Stress, and Their Influence on Cognitive Functions in Healthy and Sub-clinically Anxious Populations</brief_title>
  <official_title>The Relationship Between Common Psychiatric Drugs and Stress, and Their Influence on Cognitive Functions in Healthy and Sub-clinically Anxious Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Eldad Yechiam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beer Yaakov and Ness Ziona Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technion, Israel Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The experiment is aimed to examine the effect of common psychiatric drugs on several
      cognitive functions, in a healthy and subclinical adult population. The investigators
      hypothesize that baseline stress level regulates drugs effects on cognitive performance.
      Additionally, different levels of stress may moderate the drugs-cognition relations. In
      order to examine our hypotheses, the investigators focus on two anxiolytic drugs: herbal
      based (Hypericum) and benzodiazepine (Alprazolam). about 160 healthy (and/or subclinically
      anxious) subjects (aged 18-40) will be administered with single dose of the drugs (between
      subjects) on two different experiment dates - so subject that will be administered with a
      drug will receive placebo on the second date, or vice versa. The design will be double blind
      and second experiment day will occur at least 14 days after the first. Prior to
      administration, the investigators will measure depression and trait anxiety and state stress
      and anxiety, using inventories and cortisol in saliva test. Subjects will undergo a battery
      of computerized cognitive tests measuring working memory, attention, executive control,
      visual perception and long term memory. State anxiety and stress will be also measured
      before and after the battery. A gentle stress manipulation will be conducted during some of
      the tests.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Go/no-go task</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A computerized cognitive task: aimed to measure attention and impulsivity: errors of omission and commission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Paired association learning task</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A computerized cognitive task; percentage of memorizing pairs of words along the battery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Iowa Gambling task</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A computerized cognitive task; will be conducted in two conditions: regular and fast.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Digit span task</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A computerized cognitive task; accuracy of recalling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change detection task</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A computerized cognitive task; accuracy of responses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Operation span task</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A computerized cognitive task; accuracy of responses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Holt-Laury risk taking assessment</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A computerized task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DASS-21</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A self-report questionnaire; scoring of relevant state anxiety items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANAS</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A self-report questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAI</measure>
    <time_frame>one-two hours after drug administration</time_frame>
    <description>A self-report questionnaire; scoring of relevant state anxiety items</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Subclinical Anxious Adults</condition>
  <condition>Nootropic Potential of Hypericum and Alprazolam</condition>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Hypericum perforatum extract (Remotiv, 250 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypericum perforatum extract (Remotiv, 500 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprazolam (Xanagis, 0.25 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprazolam (Xanagis, 0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypericum perforatum extract</intervention_name>
    <arm_group_label>Hypericum perforatum extract (Remotiv, 250 mg)</arm_group_label>
    <arm_group_label>Hypericum perforatum extract (Remotiv, 500 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <arm_group_label>Alprazolam (Xanagis, 0.25 mg)</arm_group_label>
    <arm_group_label>Alprazolam (Xanagis, 0.5 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adults 18 to 40 years old.

        Exclusion Criteria:

          -  1. Demographics: Under 18 years of age or older than 40; pregnant or nursing women;
             non-fluent Hebrew speakers.

             2. Body weight: less than 50 kg and more than 90 kg (to ensure effective drug
             dosage).

             3. Mental health: Diagnosed with any DSM-V disorder (including ADHD, learning
             disabilities). These DSM-V disorders may be included in the research: sexual
             dysfunctions, sleeping disorders and mild-moderate anxiety disorders.

             4. Any motor disability hampering a participant's ability to perform the experimental
             task.

             5. Consumption of any psychoactive substance within the last 72 hours. 6. Ongoing
             medical problems or use of any substances (e.g., other prescribed medications) which
             may interact negatively with any of the three drugs used in the experiment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mili Bar-Shaked, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beer Yaakov and Ness Ziona Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eldad Yechiam, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Technion, Israel Institute of Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Ben-Eliezer, MA</last_name>
    <phone>972-4-8293057</phone>
    <email>danielbe@tx.technion.ac.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Technion, Israel Institute of Technology</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Ben Eliezer, MA</last_name>
      <phone>972-4-8293057</phone>
      <email>danielbe@tx.technion.ac.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 4, 2016</lastchanged_date>
  <firstreceived_date>July 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Technion, Israel Institute of Technology</investigator_affiliation>
    <investigator_full_name>Prof. Eldad Yechiam</investigator_full_name>
    <investigator_title>Associate Professor, Behavioral Science</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
